Tagged with R

Poland Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a…

Lithuania Vytautas Baublys, co-founder and CEO of Softneta, introduces the award-winning Lithuanian IT company, and its service offering, explaining how software-based specialized healthcare solutions improve the quality of patient care. Further, he discusses the importance of the company’s FDA-approved platform, facilitating the communication flow between scientists, doctors and patients, allowing them…

Canada Nadurel Pharma, headquartered in the technopole of Saint–Hyacinthe, Quebec, promotes natural health products complete with concrete clinical trial evidence. Martin Dufour, President and CEO, has been at the helm since 2013, over which time he has introduced the European known GeloMyrtol® and come across challenges in promoting natural health, while…

India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…

India Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities that Cipla sees as a specialty pharmaceutical company in the US.   The opportunity to service such a vast patient…

Baltics Janis Silins of the Association of Biopharmaceutical Drug Manufacturers in Latvia discusses the organization’s purpose, collaboration efforts, and role in shaping policy reform. Could you please start by introducing the Association of Biopharmaceutical Drug Manufacturers in Latvia (Biofarmaceitisko Ražotāju Asociācijas Latvijā (BRAL)) and your role within the association? “We strive…

Ecuador Roberto Aspiazu, executive director of the Ecuadorian Business Committee and honorary president of the Mexican Chamber of Commerce in Ecuador, comments on the country’s economic outlook and international trade relations with Mexico, the urgent need for Ecuador to shift its growth paradigm towards increased private investment and explains how the…

Canada Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the tenth anniversary of the company. He further highlights how Mint’s portfolio of boutique generics is sure to grow over the coming years to meet the specific needs…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…

Lithuania Jūratė Sabalienė, who was appointed in September 2017 as the director of the National Health Insurance Fund (NHIF) of the Republic of Lithuania, explains her commitment as well as the back-up strategy to ensure the access to medicines of all Lithuanian patients in a financially sustainable manner. Could you please…

Poland Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She highlights the niche approach of the company to the marketplace, challenges in Polish healthcare and the future aspirations of Pharm&Med…

Serbia Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview Skuljec tells the story of MSD’s journey from humble origins to one of the big pharma players in Serbia, growth…